Publications by authors named "E Rampakakis"
Article Synopsis
- The study aimed to assess the effectiveness of guselkumab, an antibody targeting interleukin-23p19, in treating patients with active psoriatic arthritis (PsA) who didn't respond adequately to 1-2 tumor necrosis factor inhibitors.
- In the Phase IIIb COSMOS trial, 285 adults were randomly assigned to receive either guselkumab or a placebo, with results showing significant improvements in disease activity as measured by various composite indices, particularly at Week 24.
- By Week 48, higher rates of low disease activity and remission were observed in patients taking guselkumab compared to those on placebo, indicating that guselkumab is effective even after previous treatment failures with
Purpose: Arthrogryposis multiplex congenita (AMC) describes a heterogeneous group of rare congenital conditions. Health-related quality of life (HRQL) may be reduced in AMC due to broadly heterogeneous physical impairments and participation limitations. This study described HRQL in children and youth with AMC, compared HRQL between child self- and parent-proxy reports, and identified factors associated with better/worse HRQL.
View Article and Find Full Text PDFArticle Synopsis
- The phase 3 DISCOVER-2 trial evaluated the effectiveness of guselkumab in treating psoriatic arthritis (PsA), focusing on individual patient outcomes rather than just group trends.
- Post hoc analyses showed that a high percentage (93% to 99%) of patients maintained significant clinical improvements in joint disease at scheduled dosing visits and sustained these improvements over time.
- Guselkumab demonstrated long-lasting benefits, with many patients continuing to experience improvements 100 weeks after achieving clinical milestones, indicating its potential as a robust treatment option for PsA.
Introduction: Patterns of treatment response can inform clinical decision-making. This study assessed the course and impact of achieving minimal clinically important improvement (MCII) in clinical measures and patient-reported outcomes (PROs) with guselkumab in patients with active psoriatic arthritis (PsA).
Methods: Post hoc analyses evaluated 1120 patients with PsA receiving guselkumab every 4 or 8 weeks (Q4W/Q8W) or placebo from DISCOVER-1 (31% tumor necrosis factor inhibitor-experienced) and DISCOVER-2 (biologic-naïve).
Objectives: Evaluate patterns of stringent disease control with 2 years of guselkumab across key disease-identified domains and patient-reported outcomes (PROs) in subgroups of patients with psoriatic arthritis (PsA) defined by baseline characteristics.
Method: This post hoc analysis of DISCOVER-2 (Clinicaltrials.gov NCT03158285) evaluated biologic-naïve PsA patients (≥ 5 swollen/ ≥ 5 tender joints, C-reactive protein [CRP] ≥ 0.